The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2017 | Early clinical trials of immunotherapy treatment combinations
Prof Jürgen Wolf, MD, University Hospital of Cologne, Cologne, Germany, talks about early clinical trials investigating combinations of immune checkpoint inhibitors with other immune-stimulatory molecules and other modulators of interactions in the immune system. Other areas of investigation examine combinations of immunotherapy with chemotherapy, or with radiotherapy. Prof Wolf highlights that predictive biomarkers need to be identified to guide combination treatment.
Recorded at the 2017 meeting of the British Thoracic Oncology Group (BTOG) in Dublin, Ireland.
